Aviragen Therapeutics, Inc. News (NASDAQ:AVIR)

DateTimeSource
Headline
11/29/20177:00AMGLOBEAviragen Therapeutics Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of Teslexivir (BTA074) for the Tre...
ATLANTA, Nov. 29, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a company focused on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options, today announced the completion of patient enrollment in its Phase 2 CT4 clinical trial evaluating... More...>>
11/29/20177:00AMGLOBEAviragen Therapeutics Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of Teslexivir (BTA074) for the Tre...
ATLANTA, Nov. 29, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a company focused on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options, today announced the completion of patient enrollment in its Phase 2 CT4 clinical trial evaluating... More...>>
11/02/20177:00AMGLOBEAviragen Therapeutics Reports First Quarter of Fiscal Year 2018 Financial Results
ATLANTA, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced its financial results for the three months ended September 30, 2017. “Earlier this week we were pleased to announce the culmination of our strategic review process with the signing of a definitive merger agreement with... More...>>
10/30/20177:00AMGLOBEAviragen Therapeutics and Vaxart Enter into Merger Agreement
 Merged Company to Focus on Development of Antiviral Vaccines and Therapeutics Based on Proprietary Delivery Technology Platform Conference Call to be Held Today at 8:30 AM ET  ATLANTA and SOUTH SAN FRANCISCO, Calif., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a company focused on the... More...>>
08/31/20174:01PMGLOBEAviragen Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results
ATLANTA, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced its financial results for the three months and fiscal year ended June 30, 2017. “We have made great strides, working with our Board and financial advisors, in honing in on a select number of strategic alternatives,”... More...>>
07/17/20178:00AMGLOBEBio-Path Holdings Appoints Mark Colonnese to its Board of Directors
HOUSTON, July 17, 2017 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the appointment of Mark Colonnese, Chief Financial... More...>>
05/04/20177:00AMGLOBEAviragen Therapeutics Reports Third Quarter Fiscal Year 2017 Financial Results
ATLANTA, May 04, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced its financial results for the three month period ended March 31, 2017, which is the third quarter of the Company's 2017 fiscal year. “We are expeditiously working with our Board and financial advisors to consider... More...>>
04/04/20176:00AMGLOBEAviragen Therapeutics Announces Review of Strategic Alternatives and Provides Corporate Update
ATLANTA, April 04, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a company focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options, today announced that based on a review of the status of its internal programs... More...>>
02/13/20174:01PMGLOBEAviragen Therapeutics Announces Top-Line Results from Phase 2b SPIRITUS Trial of Vapendavir
ATLANTA, Feb. 13, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics (NASDAQ:AVIR), a company focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options, today announced top-line data from its Phase 2b SPIRITUS trial, a multi-center... More...>>
02/02/20174:01PMGLOBEAviragen Therapeutics Reports Second Quarter Fiscal Year 2017 Financial Results
ATLANTA, Feb. 02, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced its financial results for the three month period ended December 31, 2016, which is the second quarter of the Company's 2017 fiscal year, and also provided an update on recent corporate developments. “In looking to... More...>>
02/01/20174:30PMGLOBEAviragen Therapeutics Announces Top-Line Results from Phase 2a RSV Challenge Study of BTA585
ATLANTA, Feb. 01, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (Nasdaq:AVIR), a company focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options, today announced top-line data from its double-blind, placebo-controlled Phase... More...>>
01/26/20174:01PMGLOBEAviragen Therapeutics to Host Conference Call to Report Second Quarter Fiscal Year 2017 Financial Results on February 2, 2017...
ATLANTA, Jan. 26, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a pharmaceutical company that is developing the next generation of antivirals, today announced that management will host a conference call on Thursday, February 2, 2017 at 4:30 p.m. ET to review the Company’s financial results for the... More...>>
01/09/20176:00AMGLOBEImmunomedics Announces Reconstituted Board of Directors and Leadership Succession Plan
-- Appoints Four New, Highly Qualified Independent Directors: Jason Aryeh, Dr. Geoffrey Cox, Robert Forrester and Bob Oliver --– -- Announces Chairman and CEO Succession Plans --– -- Mails Letter and Supplement to the Proxy Statement to Stockholders --– -- Files Supplement to Proxy Statement for Annual Meeting to... More...>>
11/09/20164:01PMGLOBEAviragen Therapeutics to Present at Stifel 2016 Healthcare Conference
ATLANTA, Nov. 09, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a pharmaceutical company that is developing the next generation of antivirals, today announced that Aviragen’s CFO & Executive Vice President Mark Colonnese will present a corporate overview at the Stifel 2016 Healthcare Conference... More...>>
11/03/20164:01PMGLOBEAviragen Therapeutics Reports First Quarter Fiscal Year 2017 Financial Results
ATLANTA, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced its financial results for the three month period ended September 30, 2016, which is the first quarter of the Company's 2017 fiscal year, and also provided an update on recent corporate developments. “Throughout the... More...>>
10/27/20164:39PMGLOBEAviragen Therapeutics to Host Conference Call to Report First Quarter Fiscal Year 2017 Financial Results on November 3, 2016
ATLANTA, Oct. 27, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a pharmaceutical company that is developing the next generation of antivirals, today announced that management will host a conference call on Thursday, November 3, 2016 at 4:30 p.m. ET to review the Company’s financial results for the... More...>>
10/10/20169:00AMGLOBEAviragen Therapeutics to Host KOL Meeting on HRV Infections on October 13, 2016 in New York
ATLANTA, Oct. 10, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a pharmaceutical company that is developing the next generation of antivirals, announced today that it will host a Key Opinion Leader (KOL) breakfast focused on the growing burden of human rhinovirus (HRV) infections in at-risk patient... More...>>
09/14/20164:01PMGLOBEAviragen Therapeutics Reports Fourth Quarter and Fiscal Year 2016 Financial Results
ATLANTA, Sept. 14, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced its financial results for the fourth quarter and 2016 fiscal year ended June 30, 2016, and also provided an update on recent corporate and clinical developments. “Over the last twelve months we have made significant... More...>>
09/13/20167:00PMGLOBEAviragen Therapeutics Announces Rescheduled Date and Time of Fourth Quarter and Fiscal Year 2016 Financial Results on Septemb...
ATLANTA, Sept. 13, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, today announced that management will host a conference call on Wednesday, September 14, 2016 at 4:30 p.m. ET to review... More...>>
09/07/20169:00AMGLOBEAviragen Therapeutics to Present at Upcoming Investor Conferences
ATLANTA, Sept. 07, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, announced today that Aviragen's CEO & President Joseph Patti, PhD will present a corporate overview at the... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V:us D:20171216 16:33:28